Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Incyte (1INCY) Stock Price & Analysis

2 Followers

1INCY Stock Chart & Stats

€108.90-€2.30(-2.07%)
At close: 5:30 PM GMT+1
€100€105€110Aug 20Sep 3Sep 11Sep 25Oct 13Oct 26Nov 12
Day’s Range
EUR 108.30 - EUR 109.35
52-Week Range
EUR 46.00 - EUR 165.00
Previous Close
EUR 111.20
Volume
N/A
Average Volume (3M)
12
Market Cap
EUR 22.37B
Enterprise Value
EUR 20.85B
Total Cash (Recent Filing)
EUR 3.85B
Total Debt (Recent Filing)
EUR 37.41M
Price to Earnings (P/E)
57.6
Beta
0.25
Next Earnings
Feb 09, 2027 (Est.)
EPS Estimate
1.7
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

High-Margin, Low-Leverage Model

Exceptionally high gross margins provide substantial economics on marketed medicines, while minimal leverage preserves financial flexibility. This combination supports continued research investment, strengthens downside protection, and gives Incyte capacity to fund development without relying heavily on external financing.

Broad-Based Commercial Growth

Growth across every product and especially rapid expansion outside Jakafi indicate that Incyte is building a broader commercial base. A larger portfolio can reduce dependence on one medicine, improve revenue durability, and provide more opportunities to leverage its specialty commercial platform.

Expanding Pipeline And Regulatory Reach

A broad late-stage pipeline and advancing regulatory programs create multiple potential sources of future growth beyond current products. European dermatology expansion and positive povorcitinib progress also increase the addressable market and diversify Incyte's long-term revenue base.

Bears Say

Volatile Profitability And Cash Generation

Although Incyte remains cash-generative, the sharp TTM free-cash-flow decline and lower operating cash conversion reduce confidence in near-term cash durability. Recent margin moderation and historical swings also make earnings less predictable, potentially limiting internally funded investment flexibility.

Jakafi Pricing Pressure

The gap between underlying Jakafi demand and reported sales growth shows that pricing and reimbursement dynamics can absorb part of volume-driven expansion. Because Jakafi remains a significant contributor, persistent pricing pressure could constrain portfolio growth even when patient demand remains healthy.

Pipeline Prioritization And Development Risk

Stopping a planned Phase 3 study narrows the development path for a potential ovarian-cancer opportunity and illustrates the need to allocate resources selectively across a large pipeline. Repeated prioritization decisions could reduce the number of shots on goal supporting future growth.

Incyte News

1INCY FAQ

What was Incyte’s price range in the past 12 months?
Incyte lowest stock price was €46.00 and its highest was €165.00 in the past 12 months.
What is Incyte’s market cap?
Incyte’s market cap is €22.37B.
When is Incyte’s upcoming earnings report date?
Incyte’s next earnings report is estimated for Feb 09, 2027 (not yet confirmed), which is in 86 days.
How were Incyte’s earnings last quarter?
Incyte released its earnings results on Oct 29, 2026. The company reported -€3.223 earnings per share for the quarter, beating the consensus estimate of -€3.522 by €0.299.
Is Incyte overvalued?
According to Wall Street analysts Incyte’s price is currently Undervalued.
Does Incyte pay dividends?
Incyte does not currently pay dividends.
What is Incyte’s EPS estimate?
Incyte’s EPS estimate is 1.70.
How many shares outstanding does Incyte have?
Incyte has 203,832,490 shares outstanding.
What happened to Incyte’s price movement after its last earnings report?
Incyte reported an EPS of -€3.223 in its last earnings report, beating expectations of -€3.522. Following the earnings report the stock price went down -0.525%.
Which hedge fund is a major shareholder of Incyte?
Hedge funds hold Incyte shares: the largest hedge-fund position in Incyte is 876,632,321 shares, and hedge funds decreased their holdings by 252.4K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology